Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China
· Delayed Price · Currency is CNY 27.85
+0.24 (0.87%)
Apr 29, 2026, 2:35 PM CST
SHE:300204 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 203.92 | 220.23 | 324.75 | 364.04 | 548.99 | 584.28 | Upgrade
|
| Other Revenue | - | - | 0.07 | 0.13 | - | 0.01 | Upgrade
|
| Revenue | 203.92 | 220.23 | 324.82 | 364.18 | 548.99 | 584.29 | Upgrade
|
| Revenue Growth (YoY) | -30.41% | -32.20% | -10.81% | -33.66% | -6.04% | 37.41% | Upgrade
|
| Cost of Revenue | 46.55 | 50.08 | 62.27 | 74.6 | 101.77 | 116.43 | Upgrade
|
| Gross Profit | 157.37 | 170.15 | 262.55 | 289.57 | 447.22 | 467.86 | Upgrade
|
| Selling, General & Admin | 157.34 | 164.49 | 195.91 | 248.23 | 310.77 | 336.76 | Upgrade
|
| Research & Development | 80.73 | 84.94 | 107.11 | 412.26 | 362.81 | 362.51 | Upgrade
|
| Other Operating Expenses | -0.69 | -0.87 | 4.31 | 4.21 | 6.72 | 7.82 | Upgrade
|
| Operating Expenses | 237.37 | 248.56 | 307.09 | 663.22 | 681.08 | 707.37 | Upgrade
|
| Operating Income | -80.01 | -78.41 | -44.55 | -373.64 | -233.87 | -239.51 | Upgrade
|
| Interest Expense | - | - | -0.64 | -1.17 | -0.36 | -0.65 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.14 | 0.63 | 2.65 | 7.32 | 22.19 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.24 | 0 | 0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | -12.41 | -8.9 | -0.21 | 0.02 | -0.24 | 1.46 | Upgrade
|
| EBT Excluding Unusual Items | -92.04 | -87.17 | -44.53 | -372.14 | -227.14 | -216.51 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.42 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0 | -1.46 | 0.21 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.88 | 0.88 | 0.28 | 0.3 | -0.04 | - | Upgrade
|
| Asset Writedown | -2.03 | -2.03 | -0.08 | -2.34 | -21.71 | -0.09 | Upgrade
|
| Other Unusual Items | - | - | 10.02 | 7.74 | 9.69 | 3.42 | Upgrade
|
| Pretax Income | -93.19 | -88.32 | -34.32 | -366.45 | -243.07 | -212.96 | Upgrade
|
| Income Tax Expense | -0.22 | -0.22 | 113.42 | 32.44 | -46.06 | -75.56 | Upgrade
|
| Earnings From Continuing Operations | -92.98 | -88.11 | -147.73 | -398.89 | -197.01 | -137.4 | Upgrade
|
| Minority Interest in Earnings | 9.12 | 10.34 | 2.89 | - | - | - | Upgrade
|
| Net Income | -83.86 | -77.76 | -144.84 | -398.89 | -197.01 | -137.4 | Upgrade
|
| Net Income to Common | -83.86 | -77.76 | -144.84 | -398.89 | -197.01 | -137.4 | Upgrade
|
| Shares Outstanding (Basic) | 422 | 486 | 483 | 475 | 481 | 474 | Upgrade
|
| Shares Outstanding (Diluted) | 422 | 486 | 483 | 475 | 481 | 474 | Upgrade
|
| Shares Change (YoY) | -11.76% | 0.66% | 1.67% | -1.17% | 1.42% | -0.27% | Upgrade
|
| EPS (Basic) | -0.20 | -0.16 | -0.30 | -0.84 | -0.41 | -0.29 | Upgrade
|
| EPS (Diluted) | -0.20 | -0.16 | -0.30 | -0.84 | -0.41 | -0.29 | Upgrade
|
| Free Cash Flow | -218.7 | -202.31 | -87.21 | -260.47 | -232.12 | -218.31 | Upgrade
|
| Free Cash Flow Per Share | -0.52 | -0.42 | -0.18 | -0.55 | -0.48 | -0.46 | Upgrade
|
| Gross Margin | 77.17% | 77.26% | 80.83% | 79.52% | 81.46% | 80.07% | Upgrade
|
| Operating Margin | -39.24% | -35.60% | -13.71% | -102.60% | -42.60% | -40.99% | Upgrade
|
| Profit Margin | -41.13% | -35.31% | -44.59% | -109.53% | -35.89% | -23.52% | Upgrade
|
| Free Cash Flow Margin | -107.25% | -91.86% | -26.85% | -71.52% | -42.28% | -37.36% | Upgrade
|
| EBITDA | -55.6 | -54.42 | -22.24 | -342.21 | -202.38 | -205.42 | Upgrade
|
| EBITDA Margin | -27.26% | -24.71% | -6.85% | -93.97% | -36.86% | -35.16% | Upgrade
|
| D&A For EBITDA | 24.41 | 23.99 | 22.3 | 31.44 | 31.48 | 34.09 | Upgrade
|
| EBIT | -80.01 | -78.41 | -44.55 | -373.64 | -233.87 | -239.51 | Upgrade
|
| EBIT Margin | -39.24% | -35.60% | -13.71% | -102.60% | -42.60% | -40.99% | Upgrade
|
| Revenue as Reported | - | - | 324.82 | 364.18 | 548.99 | 584.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.